<DOC>
	<DOCNO>NCT00096928</DOCNO>
	<brief_summary>This multicenter , prospective , 5-year surveillance study approximately 5000 Raptiva-treated patient approximately 500 non-Raptiva treated patient ( formerly 2500 comparison patient treat biologic therapy Raptiva ) chronic moderate severe plaque psoriasis candidate treatment Raptiva .</brief_summary>
	<brief_title>A Study Evaluate Psoriasis Outcomes Safety Events Patients With Chronic Moderate Severe Plaque Psoriasis ( RESPONSE )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have ever physician 's diagnosis chronic moderate severe plaque psoriasis candidate treatment Raptiva Are treat initiate Raptiva therapy time enrollment Be able provide write informed consent Be willing able fully participate duration patient followup ( 5 year ) Exclusion Criterion : Have previously receive least one dose Raptiva currently use restart treatment Raptiva time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>RESPONSE</keyword>
	<keyword>Raptiva</keyword>
	<keyword>efalizumab</keyword>
</DOC>